Embodiments are provided for digital dental modeling. One method embodiment includes receiving a three-dimensional data set including a first jaw and a second jaw of a three-dimensional digital dental model and receiving a two-dimensional data set corresponding to at least a portion of the first jaw and the second jaw. The method includes mapping two-dimensional data of the two-dimensional data set to the three-dimensional digital dental model by transforming a coordinate system of the two-dimensional data to a coordinate system of the three-dimensional data set. The method includes positioning the first jaw with respect to the second jaw based on the two-dimensional data mapped to the three-dimensional data set. The method includes using at least a portion of the two-dimensional data mapped to the three-dimensional data set as a target of movement of the first jaw with respect to the second jaw in the three-dimensional digital dental model.

Systems (10) for the simulation of percutaneous medical procedures are disclosed. The systems can include a simulated vasculature including a first component (24) configured to allow for introduction of a medical device into the system through an introductory port, a second component (14) connected to the first component and shaped to simulate a portion of a human vasculature, and a third component (18) connected to the second component and shaped to simulate a delivery site for the medical procedure. The system can be configured to allow for a medical device to be delivered to the third component by passing through the introductory port of the first component and passing through the second component. The system can be configured to replicate simulated conditions of use for the medical procedure. Methods for simulating a percutaneous medical procedure using a simulated vasculature are also disclosed.

A method for calculating binding free energy, where the method includes a plurality of steps each including adding a distance restraint potential between a binding calculation target molecule and a target molecule, wherein the method is a method for calculating binding free energy between the binding calculation target molecule and the target molecule using a computer, and wherein anchor points of the binding calculation target molecule in the plurality of the steps are identical anchor points, and anchor points of the target molecule in the plurality of the steps are different anchor points.

Biosensor system measurement devices used to determine the presence and/or concentration of an analyte in a sample include normalized calibration information relating output signal or signals the device generates in response to the analyte concentration of the sample to previously determined reference sample analyte concentrations. The measurement devices use this normalized calibration information to relate one or more output signals from an electrochemical or optical analysis of a sample to the presence and/or concentration of one or more analytes in the sample. The normalized calibration information includes a normalization relationship to normalize output signals measured by the measurement device of the biosensor system and at least one normalized reference correlation relating normalized output signals to reference sample analyte concentrations.

In some embodiments, the present invention provides method of identifying compounds that bind to phosphoinositol 4-phosphate adaptor protein-2 (FAPP2), including the steps of computationally identifying a compound that binds to FAPP2 using the atomic coordinates of at least the amino acids which make up the substrate binding pocket of FAPP2. Also provided are methods of designing, selecting and/or optimizing a compound that binds to FAPP2.

A method is provided that includes processing biological data using a biological simulation model, including calculating a set of measurements called indexes that measure interrelationships between hormones and/or blood test data; and analyzing from the indexes, the endocrine system by axis and in sequence along an adaptation process. The method includes running a selection algorithm from the indexes to identify biological dysfunctions across the endocrine system and the autonomous nervous system, and recommending corrective actions based on the identified biological dysfunctions. The method includes validating potential organism dysfunctions of the patient through the identified biological dysfunctions, consolidating diagnostic actions including the recommended corrective actions into a single diagnostic, and receiving selection of diagnostic actions therefrom. And the method includes assisting in selection of a therapeutic strategy applicable to each selected diagnostic action, and producing a final ready-to-use prescription with quantified dosage based thereon.

A method for detecting aggressive tumor behavior and/or increased risk for tumor metastasis generally includes analyzing a tumor sample from the subject for expression of transcripts from coding regions of the cell cycle gene cluster, the immune-1 gene cluster, or the immune-2 gene cluster; computing a sum of log.sub.2-transformed mean-centered expression values, thereby generating a Gene Cluster Expression Summary Score (GCESS) for the sample; and detecting a tumor with aggressive behavior and/or increased risk for tumor metastasis. An aggressive tumor and/or increased risk for tumor metastasis may be indicated where the cell cycle gene cluster is analyzed and the sample GCESS is greater than 0, or the immune-1 gene cluster or the immune-2 gene cluster is analyzed and the sample GCESS is less than 0.

A method for generating an immune score, the method comprising the steps of: (i) determining a qualitative and/or quantitative assessment of tumor infiltrating lymphocytes in a sample; (ii) determining a qualitative and/or quantitative assessment of T-cell receptor signaling in the sample; (iii) determining a qualitative and/or quantitative assessment of mutation burden in the sample; (iv) generating, using a predictive algorithm, an immune score based on the determined qualitative and/or quantitative assessment of tumor infiltrating lymphocytes, the determined qualitative and/or quantitative assessment of T-cell receptor signaling, and the determined qualitative and/or quantitative assessment of mutation burden.

Atomic or molecular models of the autoinhibitory interaction between JAK domains are provided along with methods using the atomic models for identifying agents that restore the autoinhibitory interaction between JAK domains.

The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.